PMID- 22086654
OWN - NLM
STAT- MEDLINE
DCOM- 20121022
LR  - 20220310
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Linking)
VI  - 118
IP  - 14
DP  - 2012 Jul 15
TI  - Comparative analyses of overall survival in patients with anaplastic lymphoma 
      kinase-positive and matched wild-type advanced nonsmall cell lung cancer.
PG  - 3579-86
LID - 10.1002/cncr.26668 [doi]
AB  - BACKGROUND: The purpose of this study was to investigate the overall survival 
      (OS) of patients with advanced ALK-positive nonsmall cell lung cancer (NSCLC) who 
      were managed in the pre-ALK inhibitor era and to compare their survival with that 
      of a matched case cohort of ALK wild-type (WT) patients. METHODS: Data from 1166 
      patients who had stage IIIB/IV NSCLC with nonsquamous histology were collected 
      from the NSCLC database of Seoul National University Hospital between 2003 and 
      2009. ALK fluorescence in situ hybridization (FISH) was used to analyze 262 
      patients who either had the WT epidermal growth factor receptor (EGFR) or were 
      nonresponders to previous EGFR tyrosine kinase inhibitor (TKI) therapy. Overall 
      survival (OS) was compared between 3 groups: 1) ALK-positive patients, 2) EGFR 
      mutation-positive patients, and 3) ALK-WT/EGFR-WT patients. Progression-free 
      survival (PFS) after first-line chemotherapy and EGFR TKIs also was analyzed. 
      RESULTS: Twenty-three patients were ALK-positive according to FISH analysis and 
      did not receive ALK inhibitors during follow-up. The median OS for ALK-positive 
      patients, EGFR mutation-positive patients, and WT/WT patients was 12.2 months, 
      29.6 months, and 19.3 months, respectively (vs EGFR mutation-positive patients, P 
      = .001; vs WT/WT, P = .127). The PFS after first-line chemotherapy for the 3 
      groups was not different. However, the PFS for patients who received EGFR TKIs 
      was shorter in ALK-positive patients compared with the other 2 groups (vs EGFR 
      mutation-positive patients, P < .001; vs WT/WT, P < .021). CONCLUSIONS: In the 
      pre-ALK inhibitor era, ALK-positive patients experienced the shortest survival, 
      although it did not differ statistically from that of WT/WT patients. Although 
      their responses to platinum-based chemotherapy were not different from comparator 
      groups, ALK-positive patients were even more resistant to EGFR TKI treatment than 
      WT/WT patients.
CI  - Copyright (c) 2011 American Cancer Society.
FAU - Lee, June Koo
AU  - Lee JK
AD  - Department of Internal Medicine, Seoul National University Hospital, Seoul, 
      Republic of Korea.
FAU - Park, Heae Surng
AU  - Park HS
FAU - Kim, Dong-Wan
AU  - Kim DW
FAU - Kulig, Kimary
AU  - Kulig K
FAU - Kim, Tae Min
AU  - Kim TM
FAU - Lee, Se-Hoon
AU  - Lee SH
FAU - Jeon, Yoon-Kyung
AU  - Jeon YK
FAU - Chung, Doo Hyun
AU  - Chung DH
FAU - Heo, Dae Seog
AU  - Heo DS
FAU - Kim, Woo-Ho
AU  - Kim WH
FAU - Bang, Yung-Jue
AU  - Bang YJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111115
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Anaplastic Lymphoma Kinase
MH  - Carcinoma, Non-Small-Cell Lung/metabolism/*mortality
MH  - Disease-Free Survival
MH  - ErbB Receptors/genetics
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/metabolism/*mortality
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Receptor Protein-Tyrosine Kinases/*metabolism
MH  - Survival Analysis
EDAT- 2011/11/17 06:00
MHDA- 2012/10/23 06:00
CRDT- 2011/11/17 06:00
PHST- 2011/08/25 00:00 [received]
PHST- 2011/10/03 00:00 [revised]
PHST- 2011/10/05 00:00 [accepted]
PHST- 2011/11/17 06:00 [entrez]
PHST- 2011/11/17 06:00 [pubmed]
PHST- 2012/10/23 06:00 [medline]
AID - 10.1002/cncr.26668 [doi]
PST - ppublish
SO  - Cancer. 2012 Jul 15;118(14):3579-86. doi: 10.1002/cncr.26668. Epub 2011 Nov 15.